Supernus Pharmaceuticals (SUPN) Gains from Investment Securities (2020 - 2026)

Supernus Pharmaceuticals (SUPN) has 7 years of Gains from Investment Securities data on file, last reported at $2.4 million in Q1 2026.

• On a quarterly basis, Gains from Investment Securities fell 68.79% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $20.2 million, a 661.81% increase from a year earlier, with the FY2025 full-year figure at $25.4 million, up 516.02% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $2.4 million, down from $17.8 million in the prior quarter.
• Over the last five years, Gains from Investment Securities for SUPN reached as high as $17.8 million in Q4 2025 and fell as low as -$4.4 million in Q2 2024.
• Historically, Gains from Investment Securities has averaged $1.3 million across 5 years, with a median of $356000.0 in 2024.
• Across the five-year window, Gains from Investment Securities slumped 651.27% in 2024 and jumped 4888.48% in 2025, its largest moves.
• Year by year, Gains from Investment Securities stood at -$2.4 million in 2022, then surged by 91.51% to -$204000.0 in 2023, then surged by 274.51% to $356000.0 in 2024, then soared by 4888.48% to $17.8 million in 2025, then slumped by 86.54% to $2.4 million in 2026.
• Per Business Quant data, the three most recent Gains from Investment Securities figures were $2.4 million in Q1 2026, $17.8 million in Q4 2025, and $7.7 million in Q1 2025.